{"entity":{"id":"paper-convert-int-j-radiat-oncol-biol-phys-2024-update","kind":"paper","name":"Long-Term Outcomes After Concurrent Once- or Twice-Daily Chemoradiation in Limited-Stage Small Cell Lung Cancer: A Brief Report From the CONVERT Trial","aka":[],"tldr":"Later report from the CONVERT trial registered as NCT00433563, in International Journal of Radiation Oncology, Biology, Physics (2024); its title describes an updated or longer-term analysis.","summary":"Purpose: CONVERT was a phase 3 international randomized clinical trial comparing once-daily (OD) and twice-daily (BD) radiation therapy (RT). This updated analysis describes the 6.5-year outcomes of these regimens delivered with conformal techniques.\n\nMethods and materials: CONVERT (NCT00433563) randomized patients 1:1 between OD RT (66 Gy/33 fractions/6.5 weeks) and BD RT (45 Gy/30 fractions/3 weeks), both delivered with concurrent cisplatin/etoposide. Three-dimensional conformal RT was mandatory, intensity-modulated RT was permitted, and elective nodal irradiation was not allowed. Prophylactic cranial irradiation was delivered at the discretion of treating clinicians. RT treatment planning was subject to central quality assurance.\n\nResults: Five hundred forty-seven patients were recruited at 73 centers. The median follow-up for the surviving cohort (n = 164) was 81.2 months. The median survival for the OD and BD arms were 25.4 months (95% CI, 21.1-30.9) and 30.0 months (95% CI, 25.3-36.5; hazard ratio, 1.13; 95% CI, 0.92-1.38; P =.247). Performance status and tumor volume were associated with survival on multivariate analysis. No treatment-related deaths occurred subsequent to the initial analysis performed in 2017. Regarding late toxicity, 7 patients in the OD arm developed grade 3 esophagitis, 4 of which went on to develop stricture or fistulation, compared with no patients in the BD arm. Grade 3 pulmonary fibrosis occurred in 2 and 3 patients in the OD and BD arms, respectively.\n\nConclusions: As the CONVERT trial did not demonstrate the superiority of OD RT and this regimen had a slightly worse toxicity profile after 80 months of follow-up, 45 Gy BD should remain the standard of care in limited stage small cell lung cancer.\n\nIndexed on Europe PMC as PubMed record 38521132 (DOI 10.1016/j.ijrobp.2024.02.063). Its abstract cites the registry id NCT00433563, which is how it was matched to this trial; no figure has been checked by an editor.","asOf":"2026-09-22","links":[{"label":"Int J Radiat Oncol Biol Phys 2024","url":"https://doi.org/10.1016/j.ijrobp.2024.02.063"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/38521132/"},{"label":"Europe PMC","url":"https://europepmc.org/article/MED/38521132"},{"label":"ClinicalTrials.gov NCT00433563","url":"https://clinicaltrials.gov/study/NCT00433563"}],"tags":["europepmc-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["convert"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["ijrobp"],"dependsOn":[],"notes":[],"journal":"International Journal of Radiation Oncology, Biology, Physics","year":2024,"doi":"10.1016/j.ijrobp.2024.02.063","pmid":"38521132","authors":"Walls GM, Mistry H, Barlesi F, et al.","paperType":"rct","findings":[],"whatItMeans":"A second publication from the CONVERT trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.","caveats":["Matched to the trial by the registry id cited in the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.","Chosen as a later report by words in its title (updated, long-term, final, overall survival or a year count), not by reading the paper."]},"route":"/key-papers/paper-convert-int-j-radiat-oncol-biol-phys-2024-update/","neighbours":{"trial":[{"id":"convert","kind":"trial","name":"CONVERT","route":"/trials/convert/"}],"journal":[{"id":"ijrobp","kind":"journal","name":"International Journal of Radiation Oncology, Biology, Physics","route":"/journals/ijrobp/"}]}}